Hennion & Walsh Asset Management Inc. Raises Stock Holdings in Autolus Therapeutics plc (NASDAQ:AUTL)

Hennion & Walsh Asset Management Inc. grew its stake in shares of Autolus Therapeutics plc (NASDAQ:AUTL - Free Report) by 48.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 386,001 shares of the company's stock after buying an additional 126,021 shares during the period. Hennion & Walsh Asset Management Inc. owned 0.15% of Autolus Therapeutics worth $598,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of AUTL. Wellington Management Group LLP boosted its stake in Autolus Therapeutics by 4.6% during the fourth quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock valued at $59,562,000 after buying an additional 1,125,454 shares during the period. TFG Asset Management GP Ltd raised its holdings in shares of Autolus Therapeutics by 3.1% in the 4th quarter. TFG Asset Management GP Ltd now owns 8,250,000 shares of the company's stock valued at $19,388,000 after acquiring an additional 250,000 shares in the last quarter. Two Sigma Advisers LP boosted its position in shares of Autolus Therapeutics by 4.8% during the 4th quarter. Two Sigma Advisers LP now owns 333,400 shares of the company's stock valued at $783,000 after acquiring an additional 15,400 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of Autolus Therapeutics by 23.8% during the 4th quarter. Two Sigma Investments LP now owns 906,767 shares of the company's stock valued at $2,131,000 after acquiring an additional 174,485 shares during the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in shares of Autolus Therapeutics during the fourth quarter worth about $581,000. 72.83% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on AUTL. Truist Financial lowered their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a research report on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $9.32.

Autolus Therapeutics Stock Performance

AUTL traded down $0.10 during midday trading on Wednesday, hitting $2.23. The stock had a trading volume of 2,058,437 shares, compared to its average volume of 1,555,698. Autolus Therapeutics plc has a 1 year low of $1.11 and a 1 year high of $5.00. The business has a fifty day moving average of $1.50 and a 200 day moving average of $1.97. The company has a market cap of $594.56 million, a P/E ratio of -1.84 and a beta of 1.76.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. On average, equities research analysts anticipate that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.